Table 2.
Efficacy of Ad5-nCoV against COVID-19 with onset at least 28 days and at least 14 days after vaccination
| Ad5-nCoV group | Placebo group | Vaccine efficacy (95% CI) | ||
|---|---|---|---|---|
| Total number of COVID-19 cases | ||||
| Beginning 28 days postvaccination | 45/10 660 (0·4%) | 105/10 590 (1·0%) | 57·5% (39·7 to 70·0) | |
| Beginning 14 days postvaccination | 77/14 591 (0·5%) | 211/14 586 (1·4%) | 63·7% (52·9 to 72·1) | |
| Number of people with severe disease from COVID-19* | ||||
| Beginning 28 days postvaccination | ||||
| 18–44 years | 0/7623 | 3/7579 (<0·1%) | 100% | |
| 45–59 years | 0/2198 | 5/2171 (0·2%) | 100% | |
| ≥ 60 years | 1/839 (0·1%) | 4/840 (0·5%) | 76·1% (−114·3 to 97·3) | |
| Beginning 14 days postvaccination | ||||
| 18–44 years | 0/10 102 | 8/10 114 (0·1%) | 100% | |
| 45–59 years | 0/3166 | 7/3125 (0·2%) | 100% | |
| ≥ 60 years | 1/1323 (0·1%) | 10/1347 (0·7%) | 90·1% (22·3 to 98·7) | |
| Total number of COVID-19 cases by age and number of days postvaccination | ||||
| Beginning 28 days postvaccination | ||||
| 18–44 years | 27/7623 (0·4%) | 69/7579 (0·9%) | 60·9% (39·1 to 75·0) | |
| 45–59 years | 11/2198 (0·5%) | 28/2171 (1·3%) | 62·2% (24·0 to 81·2) | |
| ≥ 60 years | 7/839 (0·8%) | 8/840 (1·0%) | 17·5% (−127·6 to 70·1) | |
| Beginning 14 days postvaccination | ||||
| 18–44 years | 49/10 102 (0·5%) | 143/10 114 (1·4%) | 65·8% (52·7, 75·3) | |
| 45–59 years | 18/3166 (0·6%) | 47/3125 (1·5%) | 62·7% (35·8, 78·4) | |
| ≥ 60 years | 10/1323 (0·8%) | 21/1347 (1·6%) | 53·3% (0·9, 78·0) | |
| Total number of COVID-19 cases by sex and number of days postvaccination | ||||
| Beginning 28 days postvaccination | ||||
| Male | 25/7452 (0·3%) | 73/7578 (1·0%) | 65·8% (46·1 to 78·3) | |
| Female | 20/3208 (0·6%) | 32/3012 (1·1%) | 40·0% (−4·9 to 65·7) | |
| Beginning 14 days postvaccination | ||||
| Male | 43/9797 (0·4%) | 138/10 009 (1·4%) | 68·5% (55·7 to 77·7) | |
| Female | 34/4794 (0·7%) | 73/4577 (1·6%) | 55·7% (33·5 to 70·5) | |
Ad5-nCoV=adenovirus type 5 (Ad5) vectored vaccine expressing the SARS-CoV-2 spike protein.
Severe disease is defined as a minimum of one of any of the following: clinical signs at rest indicative of severe systemic illness (respiratory rate ≥30 per min, heart rate ≥125 per min, SpO2 ≤93% on room air at sea level, or PaO2/FiO2 <300 mm Hg); respiratory failure (defined as needing high- flow oxygen, non-invasive ventilation, mechanical ventilation or extracorporeal membrane oxygenation); evidence of shock (systolic blood pressure < 90 mm Hg, diastolic blood pressure <60 mm Hg, or requiring vasopressors); significant acute renal, hepatic, or neurologic dysfunction; admission to an intensive care unit.